Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

More recent case law has reinforced this principle, holding that when therapeutic and non-therapeutic effects are inseparably ...

Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently ...

For many Americans, St. Patrick’s Day is a moment to don green apparel and indulge in drinking a few – or more than a few – ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...